Talphera, Inc.

NasdaqGM:TLPH Stock Report

Market Cap: US$11.4m

Talphera Valuation

Is TLPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TLPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TLPH's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TLPH's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TLPH?

Key metric: As TLPH is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for TLPH. This is calculated by dividing TLPH's market cap by their current revenue.
What is TLPH's PS Ratio?
PS Ratio42.7x
SalesUS$281.00k
Market CapUS$11.39m

Price to Sales Ratio vs Peers

How does TLPH's PS Ratio compare to its peers?

The above table shows the PS ratio for TLPH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.5x
BIOE Bio Essence
33.2xn/aUS$10.4m
PRPH ProPhase Labs
1.4x86.3%US$18.1m
SLGL Sol-Gel Technologies
1x27.7%US$12.0m
RDHL RedHill Biopharma
2.2xn/aUS$8.8m
TLPH Talphera
42.7x75.2%US$11.4m

Price-To-Sales vs Peers: TLPH is expensive based on its Price-To-Sales Ratio (42.7x) compared to the peer average (9.5x).

Price to Sales Ratio vs Industry

How does TLPH's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

73 CompaniesPrice / SalesEstimated GrowthMarket Cap
OGN Organon
0.6x-0.06%US$3.76b
PRGO Perrigo
0.8x3.4%US$3.72b
BHC Bausch Health Companies
0.3x1.5%US$3.01b
AMRX Amneal Pharmaceuticals
1x5.6%US$2.62b
TLPH 42.7xIndustry Avg. 2.5xNo. of Companies73PS048121620+
73 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: TLPH is expensive based on its Price-To-Sales Ratio (42.7x) compared to the US Pharmaceuticals industry average (2.5x).

Price to Sales Ratio vs Fair Ratio

What is TLPH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TLPH PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio42.7x
Fair PS Ratio0.00006x

Price-To-Sales vs Fair Ratio: TLPH is expensive based on its Price-To-Sales Ratio (42.7x) compared to the estimated Fair Price-To-Sales Ratio (0x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TLPH forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.71
US$4.17
+489.8%
31.5%US$6.00US$3.00n/a3
Nov ’25US$0.92
US$4.17
+352.8%
31.5%US$6.00US$3.00n/a3
Oct ’25US$0.85
US$4.17
+389.8%
31.5%US$6.00US$3.00n/a3
Sep ’25US$1.04
US$4.17
+300.6%
31.5%US$6.00US$3.00n/a3
Aug ’25US$0.93
US$4.42
+373.6%
27.9%US$6.00US$3.00n/a3
Jul ’25US$0.92
US$4.42
+382.0%
27.9%US$6.00US$3.00n/a3
Jun ’25US$1.03
US$4.42
+328.8%
27.9%US$6.00US$3.00n/a3
May ’25US$1.00
US$5.13
+412.5%
17.1%US$6.00US$4.25n/a2
Apr ’25US$1.07
US$5.13
+379.0%
17.1%US$6.00US$4.25n/a2
Mar ’25US$1.31
US$5.13
+291.2%
17.1%US$6.00US$4.25n/a2
Feb ’25US$1.05
US$5.13
+388.1%
17.1%US$6.00US$4.25n/a2
Jan ’25US$0.73
US$4.63
+529.3%
8.1%US$5.00US$4.25n/a2
Dec ’24US$0.76
US$4.63
+505.4%
8.1%US$5.00US$4.25n/a2
Nov ’24US$0.53
US$4.63
+774.1%
8.1%US$5.00US$4.25US$0.922

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

IQVIA Holdings

US$34.7b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$194.38

7D

-8.1%

1Y

-7.2%

Collegium Pharmaceutical

US$959.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.00

7D

-0.6%

1Y

15.5%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.10

7D

-7.9%

1Y

6.6%